KRAS and acute lymphoblastic leukemia: After our metabolite rescue and chemical inhibitor studies demonstrated impacts of this metabolic rewiring on B-ALL cell growth, we found that chemically inhibiting the AKT/mTOR pathway can rescue the mutant KRAS-induced amino acid metabolism disruption and promote the in vivo growth of KRAS-mutant B-ALL cells (Figure 6F).